AP-PA02
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-cystic Fibrosis Bronchiectasis
Conditions
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Trial Timeline
Jan 10, 2023 → Aug 8, 2024
NCT ID
NCT05616221About AP-PA02
AP-PA02 is a phase 2 stage product being developed by Armata Pharmaceuticals for Non-cystic Fibrosis Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05616221. Target conditions include Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05616221 | Phase 2 | Completed |
| NCT04596319 | Phase 1/2 | Completed |
Competing Products
8 competing products in Non-cystic Fibrosis Bronchiectasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| TIP + TIP and placebo + Placebo | Novartis | Phase 2 | 52 |
| CSL787 + Placebo | CSL | Phase 2 | 51 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 74 |
| HSK31858 + placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 2 | 49 |
| Brensocatib | Insmed | Pre-clinical | 20 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 3 | 74 |